当前位置: X-MOL 学术Nat. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome.
Nature Medicine ( IF 58.7 ) Pub Date : 2019-02-18 , DOI: 10.1038/s41591-019-0343-4
Ergin Beyret 1 , Hsin-Kai Liao 1 , Mako Yamamoto 1, 2 , Reyna Hernandez-Benitez 1 , Yunpeng Fu 1 , Galina Erikson 1 , Pradeep Reddy 1 , Juan Carlos Izpisua Belmonte 1
Affiliation  

Hutchinson-Gilford progeria syndrome (HGPS) is a rare lethal genetic disorder characterized by symptoms reminiscent of accelerated aging. The major underlying genetic cause is a substitution mutation in the gene coding for lamin A, causing the production of a toxic isoform called progerin. Here we show that reduction of lamin A/progerin by a single-dose systemic administration of adeno-associated virus-delivered CRISPR-Cas9 components suppresses HGPS in a mouse model.

中文翻译:

单剂量 CRISPR-Cas9 疗法可延长患有 Hutchinson-Gilford 早衰综合症小鼠的寿命。

哈钦森-吉尔福德早衰综合症 (HGPS) 是一种罕见的致命遗传性疾病,其特征是让人联想到加速衰老的症状。主要的潜在遗传原因是编码核纤层蛋白 A 的基因发生替代突变,导致产生一种称为早老素的有毒亚型。在这里,我们证明,通过单剂量全身施用腺相关病毒递送的 CRISPR-Cas9 成分来减少核纤层蛋白 A/早老蛋白,可以抑制小鼠模型中的 HGPS。
更新日期:2019-02-19
down
wechat
bug